CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week
Post# of 62
Posted On: 11/20/2014 11:14:34 AM
CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of 5.56 Closing the day 10:45 at 5.76 -0.19 -3.19% With a day low of 5.56 and a total volume of 41,986.
CGIX Recent Posts: http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/
CGIX Cancer Genetics Inc Recent Headline News
Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Mon Nov 17, 6:50AM CST
-- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. Recognized in Deloitte's 2014 Technology Fast 500(TM) Awards
GlobeNewswire - Fri Nov 14, 7:06AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"
, an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
GlobeNewswire - Thu Nov 13, 6:55AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company's CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, November 20, will profile over 80 public and private med-tech and diagnostic companies.
CGIX: 5.73 (-0.22)
Cancer Genetics wins second patent for FHACT test to improve cervical cancer detection for up to 2m women in the US each year
M2 - Wed Nov 12, 7:02AM CST
Cancer diagnostics company Cancer Genetics (NasdaqCM:CGIX) disclosed on Tuesday the receipt of the second US patent (US Patent No. 8,883,414) for its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.
CGIX: 5.73 (-0.22)
RedChip Issues Research Note on Cancer Genetics
GlobeNewswire - Wed Nov 12, 7:00AM CST
RedChip Companies, Inc., today announced it has issued a research note on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP
GlobeNewswire - Wed Nov 12, 6:55AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company'sNGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT(R)
GlobeNewswire - Tue Nov 11, 6:55AM CST
-- Company receives second patent (US Patent No. 8,883,414) for FHACT(R)
CGIX: 5.73 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.32 (-0.01), JRJC: 6.87 (+0.13), NAVB: 1.21 (-0.01), SANW: 3.68 (+0.16), PLPM: 1.60 (+0.02), RYN: 26.89 (+0.48), INFU: 2.87 (+0.02), LIOX: 5.08 (+0.12), DY: 25.97 (+0.30), MTZ: 24.55 (+0.45), CGIX: 5.73 (-0.22), MUX: 1.51 (+0.05), OREX: 5.67 (-0.01), URRE: 2.14 (unch), ACHN: 13.12 (+0.21), REN: 2.62 (+0.13), MPO: 2.82 (+0.17), AKBA: 14.50 (-0.74), TRX: 1.15 (+0.08), PLNR: 7.27 (+0.04)
Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:28AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:03AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 5.73 (-0.22)
Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 5.73 (-0.22)
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company" , an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 5.73 (-0.22)
Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 5.73 (-0.22)
CGIX Recent Posts: http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/
CGIX Cancer Genetics Inc Recent Headline News
Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Mon Nov 17, 6:50AM CST
-- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. Recognized in Deloitte's 2014 Technology Fast 500(TM) Awards
GlobeNewswire - Fri Nov 14, 7:06AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"
, an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period. CGIX: 5.73 (-0.22)
Cancer Genetics Inc to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
GlobeNewswire - Thu Nov 13, 6:55AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company's CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, November 20, will profile over 80 public and private med-tech and diagnostic companies.
CGIX: 5.73 (-0.22)
Cancer Genetics wins second patent for FHACT test to improve cervical cancer detection for up to 2m women in the US each year
M2 - Wed Nov 12, 7:02AM CST
Cancer diagnostics company Cancer Genetics (NasdaqCM:CGIX) disclosed on Tuesday the receipt of the second US patent (US Patent No. 8,883,414) for its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.
CGIX: 5.73 (-0.22)
RedChip Issues Research Note on Cancer Genetics
GlobeNewswire - Wed Nov 12, 7:00AM CST
RedChip Companies, Inc., today announced it has issued a research note on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP
GlobeNewswire - Wed Nov 12, 6:55AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company'sNGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders. CGIX: 5.73 (-0.22)
Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT(R)
GlobeNewswire - Tue Nov 11, 6:55AM CST
-- Company receives second patent (US Patent No. 8,883,414) for FHACT(R)
CGIX: 5.73 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.32 (-0.01), JRJC: 6.87 (+0.13), NAVB: 1.21 (-0.01), SANW: 3.68 (+0.16), PLPM: 1.60 (+0.02), RYN: 26.89 (+0.48), INFU: 2.87 (+0.02), LIOX: 5.08 (+0.12), DY: 25.97 (+0.30), MTZ: 24.55 (+0.45), CGIX: 5.73 (-0.22), MUX: 1.51 (+0.05), OREX: 5.67 (-0.01), URRE: 2.14 (unch), ACHN: 13.12 (+0.21), REN: 2.62 (+0.13), MPO: 2.82 (+0.17), AKBA: 14.50 (-0.74), TRX: 1.15 (+0.08), PLNR: 7.27 (+0.04)
Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:28AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:03AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 5.73 (-0.22)
Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 5.73 (-0.22)
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 5.73 (-0.22)
Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina. CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 5.73 (-0.22)
Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT). CGIX: 5.73 (-0.22)
Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking. CGIX: 5.73 (-0.22)
(0)
(0)Vyant Bio, Inc. (VYNT) Stock Research Links
Scroll down for more posts ▼